Please ensure Javascript is enabled for purposes of website accessibility

Why Heat Biologics, Inovio Pharmaceuticals, and Novavax Are Getting Clobbered Today

By George Budwell – Aug 24, 2020 at 10:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Reports of an early approval for AstraZeneca's COVID-19 vaccine are sending these three stocks lower today.

What happened

Shares of the COVID-19 vaccine players Heat Biologics (HTBX 0.00%), Inovio Pharmaceuticals (INO -3.39%), and Novavax (NVAX -6.42%) are all starting the week off on a sour note. Heat Biologics' stock is down by 13%, Inovio's shares are under water by 10.6%, and Novavax's equity is in the red by 11.1% as of 10:09 a.m EDT Monday morning. 

What's spooking investors? Reports surfaced over the weekend that President Donald Trump may green-light AstraZeneca's (AZN -3.07%) experimental COVID-19 vaccine by October. The approval, if it happens, would likely occur through a mechanism known as an emergency use authorization (EUA).

A man getting punched in the face.

Image source: Getty Images.

So what

On Sunday, the Food and Drug Administration announced the EUA of convalescent plasma therapy, a move that seems to be stoking fears among investors in vaccine companies that aren't quite as far along as AstraZeneca in terms of clinical development. Put simply, AstraZeneca may leapfrog these second-tier players through an EUA. 

Heat Biologics has so far released promising pre-clinical data for its heat shock protein based COVID-19 vaccine. But an early-stage trial isn't slated to kick off until the first quarter of 2021. Inovio, on the other hand, plans to initiate a phase 2/3 trial later this year for its COVID-19 vaccine candidate known as INO-4800. Finally, Novavax's COVID-19 candidate, NVX‑CoV2373, has only completed a phase 1 trial up to this point. 

So AstraZeneca does indeed have a good chance at beating all three of these companies to the punch -- that is, if these rumors of an EUA turn out to be true.  

Now what

Should bargain hunters pounce on any of these beaten-down coronavirus stocks today? It's hard to say. There are a lot of moving parts on the vaccine development front. Researchers don't even fully understand the respective roles of innate versus adaptive immunity when it comes to this particular virus. That leaves a lot of room for late-comers such as Heat Biologics, Inovio, and Novavax.

Bottom line: AstraZeneca's vaccine -- if approved under EUA -- probably won't be a showstopper for these other companies. So, if you're risk-tolerant, it might be worthwhile to pick up a few shares of one or more of these coronavirus vaccine stocks today.

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$21.00 (-6.42%) $-1.44
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.71 (-3.39%) $0.06
Heat Biologics, Inc. Stock Quote
Heat Biologics, Inc.
HTBX
$1.79 (0.00%) $0.00
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.58 (-3.07%) $-1.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.